Oxcarbazepine add-on for drug-resistant partial epilepsy

Castillo, Sergio M; Schmidt, Dieter; White, Sarah; Shukralla, Arif

doi:10.1002/14651858.cd002028.pub2

Cited by 4 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The newer drugs have been demonstrated to be more effective with respect to seizure control and associated with a higher incidence of overall adverse effects and withdrawal rates than placebo. [25][26][27][28][29][30][31][32][33][34][35][36][37] There is little evidence, however, of how these AEDs should be trialed when monotherapy fails, and in which order they should be prescribed as an adjunct, since no direct head-tohead trials are available. Although the results of this meta-analysis of randomized controlled clinical trials clearly indicated that BRV is effective to reduce the frequency of refractory partial-onset seizures and reasonably tolerated as adjunctive treatment, it cannot compare BRV to other AEDs, and the application field in the management of adult refractory epilepsy remains to be clearly established for BRV, as well as for many other newer AEDs.…”

Section: Resultsmentioning

confidence: 99%

Brivaracetam add-on for refractory focal epilepsy

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Brivaracetam add-on for refractory focal epilepsy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…23 The Cochrane database review showed that oxcarbazepine is effective as an add-on treatment in patients with drug-resistant partial epilepsy. 24 Similar to valproic acid, oxcarbazepine monotherapy may result in significant weight gain in children with epilepsy. 25 For generalized epilepsies including genetically mediated generalized epilepsies, valproic acid was considered a drug of choice because of its effectiveness on broad range of seizure types.…”

Section: Casementioning

confidence: 99%

Medical Management in Focal versus Generalized Epilepsy

Sannagowdara

Khan

2021

Journal of Pediatric Epilepsy

View full text Add to dashboard Cite

About 70% of children with new-onset epilepsy have the potential to become seizure-free on antiepileptic drug (AED) monotherapy with appropriately selected first-line medication. In ideal world, physician is expected to achieve best possible seizure control without impacting the quality of life. There is rapid increase in number of AEDs available over last couple of decades. Although not necessarily all of them are superior to old generation drugs in terms of seizure control, certainly there is change in landscape from perspective of tolerability and side-effect profile. Physicians must therefore be familiar with safety, tolerability, therapeutic effects, synergistic combinations as well as AEDs to avoid in specific circumstances. The article attempts to give general overview of available AEDs under broad umbrella of effectiveness against focal and generalized seizures as well as drugs with “broad spectrum.” The emergence of newer AEDs with broad spectrum and favorable side-effect profile is welcome. However, the future lies in better understanding of underlying diverse pathophysiology of clinical symptom “epilepsy” and developing new compounds acting on molecular targets as well as individualizing therapy. Technological advances in molecular genetics research are bringing precision medicine to the fore.

show abstract

“…Oxcarbazepine, gabapentin, zonisamide, and eslicarbazepine acetate have been reported to be effective as add-on therapy for refractory partial seizure. However, the short duration of studies makes it difficult to extrapolate to long-term treatment [62][63][64][65]. Status epilepticus is considered a common neurological emergency with a high mortality rate of 20%.…”

Section: Add-on Aedsmentioning

confidence: 99%

Evidence for Efficacy of Combination of Antiepileptic Drugs in Treatment of Epilepsy

2015

View full text Add to dashboard Cite

Epilepsy is the tendency to have recurrent, unprovoked seizures. Although 70% of epileptic seizures can be controlled with monotherapy (treatment by single antiepileptic drug), a combination of two or more anti-epileptic drugs (AEDs) may be required to improve efficacy (seizure control) and tolerability. Polytherapy (treatment with two or more AEDs) can affect efficacies and side effects in additive, supra-additive (synergistic) or infra-additive fashion. The effect is considered supraadditive when the efficacy of the combination is greater than the sum of the individual drug efficacies, while it is considered infra-additive when the efficacy of the combination is less than the sum of the individual drug efficacies. Here, we have reviewed the available studies and evidences for the application of polytherapy in humans and animal models, to understand which combination of AEDs act as a synergistic polytherapy for epilepsy. We have searched the bibliographic databases MEDLINE and PubMed for studies conducted from 1950 to 2013 and have concluded that, although promising results from the experimental point of view support the combinations of topiramate separately with lamotrigine, gabapentin and felbamate, the most reliable evidence supports the use of valproate and lamotrigine, as this combination generates encouraging results in animal models. Though effectiveness of this combination is supported by human data, there is the possibility of increased side effects. The new drugs are all effective as add-on therapy; there is some evidence that at present, in clinical practice, levetiracetam and topiramate may be the most effective add-on therapies in partial and some generalized epilepsies.

show abstract

Oxcarbazepine add-on for drug-resistant partial epilepsy

Abstract: The editorial group responsible for this previously published document have withdrawn it from publication.

Cited by 4 publications

References 15 publications

Brivaracetam add-on for refractory focal epilepsy

Brivaracetam add-on for refractory focal epilepsy

Medical Management in Focal versus Generalized Epilepsy

Evidence for Efficacy of Combination of Antiepileptic Drugs in Treatment of Epilepsy

Contact Info

Product

Resources

About